Oral bendamustine formulations
AssigneeTube Pharmaceuticals GmbH
InventorWolfgang RICHTER
Life of this patent
Estimating the term…
Abstract
The present invention relates to an oral pharmaceutical composition comprising bendamustine in combination with a modified cyclodextrin, such as, e.g., methyl-β-cyclodextrin or hydroxypropyl-β-cyclodextrin. It has surprisingly been found in the context of the invention that such compositions exhibit a greatly improved oral bioavailability, which renders them particularly advantageous for oral therapeutic application, e.g., in the treatment of cancer.
Claims24
(canceled)
An oral pharmaceutical composition comprising bendamustine or a pharmaceutically acceptable salt or solvate thereof in combination with a modified cyclodextrin, wherein said modified cyclodextrin is α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin, and wherein said α-cyclodextrin, said β-cyclodextrin or said γ-cyclodextrin is substituted with C1-4 alkyl, hydroxy-C1-4 alkyl, dihydroxy-C1-4 alkyl, —CO(C1-4 alkyl), or any combination thereof.
(canceled)
(canceled)
-21. (canceled)
A method of delivering bendamustine or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof, the method comprising orally administering a pharmaceutical composition comprising bendamustine or a pharmaceutically acceptable salt or solvate thereof in combination with a modified cyclodextrin to the subject, wherein said modified cyclodextrin is selected from the group consisting of α-cyclodextrin,-cyclodextrin and γ-cyclodextrin, and wherein said α-cyclodextrin, said β-cyclodextrin or said γ-cyclodextrin is substituted with C1-4 alkyl, hydroxy-C1-4 alkyl, dihydroxy-C1-4 alkyl, —CO(C1-4 alkyl), or any combination thereof.
Dependencies are inferred from the claim text.